Previous studies of risk factors for CMV infection and associated treatment strategies have mainly focused on transplant[28] and acquired immune deficiency syndrome (AIDS) patients.[29] Among patients with AIDS and a history of CMV, secondary prophylaxis of CMV infection has been established as a beneficial strategy to avoid the severe consequences of CMV infection while the CD4+T cell count remains is below 100/μL. This evidence concerns the gene CD4 and AIDS.